Rankings
▼
Calendar
VTRS Q3 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena
VTRS
Viatris Inc.
$17B
Q3 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.9B
-3.3% YoY
Gross Profit
$1.7B
42.9% margin
Operating Income
$452M
11.5% margin
Net Income
$332M
8.4% margin
EPS (Diluted)
$0.27
QoQ Revenue Growth
+0.6%
Cash Flow
Operating Cash Flow
$835M
Free Cash Flow
$732M
Stock-Based Comp.
$43M
Balance Sheet
Total Assets
$48.7B
Total Liabilities
$27.9B
Stockholders' Equity
$20.9B
Cash & Equivalents
$1.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.9B
$4.1B
-3.3%
Gross Profit
$1.7B
$1.7B
-3.3%
Operating Income
$452M
$560M
-19.4%
Net Income
$332M
$354M
-6.4%
Revenue Segments
Brands
$2.5B
64%
Generics
$1.2B
31%
Complex GX and Biosimilars
$174M
4%
Geographic Segments
Developed Markets Segment
$2.4B
61%
Emerging Markets Segment
$643M
16%
Greater China Segment
$548M
14%
Japan, Australia and New Zealand Segment
$335M
9%
← FY 2023
All Quarters
Q4 2023 →